Juvenile Nasopharyngeal Angiofibroma: Difference between revisions

From OtoWiki
Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(44 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{infobox Disease
{{infobox Disease
|Title             =  
|Title=Juvenile Nasopharyngeal Angiofibroma
|Aliases           =  
|Aliases=JNA, Nasopharyngeal angiofibroma
|Image             = [[File:Nasopharyngeal angiofibroma - 2 - high mag.jpg]]
|Image=[[File:Nasopharyngeal angiofibroma - 2 - high mag.jpg]]
|Caption           = Histologic section of a JNA
|Caption=Histologic section of JNA showing fibrovascular stroma
|ICD-9             = 210.7
|ICD-9=210.7
|ICD-10             = D10.6
|ICD-10=D10.6
|MeSH               =  
|MeSH=D018322
|Gene               =  
|Gene=
|Locus             =  
|Locus=
|OMIM               =  
|OMIM=
|EyeWiki           =  
|EyeWiki=
|Radiopaedia       = https://radiopaedia.org/articles/juvenile-nasopharyngeal-angiofibroma?lang=us
|Radiopaedia=[https://radiopaedia.org/articles/juvenile-nasopharyngeal-angiofibroma?lang=us Juvenile Nasopharyngeal Angiofibroma]
|Pathology=[https://www.pathologyoutlines.com/topic/nasalangiofibroma.html Nasal Angiofibroma]
|Specialty=[[Otolaryngology]], [[Rhinology]], [[Skull Base Surgery]]
|Incidence=0.05-0.5% of head and neck tumors; 0.4 cases per million inhabitants/year
|Onset=9-25 years (peak 14-18 years)
|Gender=Predominantly male (95-100%)
|Classification=Benign fibrovascular tumor (locally aggressive)
|KeyMolecular=β-catenin mutations (~75%), androgen receptor expression
}}
}}


== Overview ==
== Overview ==
Juvenile nasopharyngeal angiofibroma (JNA) is a benign vascular neoplasm of the nasal cavity and nasopharynx that classically presents in adolescent boys.


== Pathophysiology ==
'''Juvenile nasopharyngeal angiofibroma''' (JNA) is a rare, histologically benign but locally aggressive vascular tumor that arises almost exclusively in adolescent males.<ref name="StatPearlsNBK545240"/> The tumor originates from the posterolateral nasal wall near the sphenopalatine foramen and characteristically extends into the nasopharynx, nasal cavity, paranasal sinuses, pterygopalatine fossa, and potentially the infratemporal fossa, orbit, and intracranial cavity.<ref name="Lloyd2000"/>
 
JNA accounts for approximately 0.05-0.5% of all head and neck tumors, with extremely rare occurrence in females.<ref name="StatPearlsNBK545240"/> It occurs predominantly in males aged 10-25 years, with peak incidence around 14-18 years.<ref name="Medscape2024"/> The classic presentation includes unilateral nasal obstruction and recurrent epistaxis. Despite its benign histology, JNA can cause significant morbidity from local invasion and is highly vascular, posing surgical challenges. Treatment is primarily surgical, often with preoperative embolization to reduce intraoperative blood loss.<ref name="Howard2001"/>
 
## History
 
Juvenile nasopharyngeal angiofibroma was first described by Hippocrates in the 5th century BC as a nasal tumor causing epistaxis. Detailed clinical and pathological descriptions followed over subsequent centuries. The term "angiofibroma" was introduced in the 19th century to describe the vascular and fibrous components of the tumor.
 
Chauveau in 1906 described the characteristic location of origin near the sphenopalatine foramen. Advances in imaging (CT, MRI, angiography) in the late 20th century improved understanding of tumor extent and surgical planning. Preoperative embolization, introduced in the 1970s, revolutionized surgical management by reducing intraoperative blood loss. Endoscopic approaches, developed in the 1990s and 2000s, have become the standard for many cases.
 
## Pathophysiology
 
=== Relevant Anatomy ===
=== Relevant Anatomy ===
'''Site of origin''':
JNA arises from the posterolateral nasal wall, specifically at or near the sphenopalatine foramen, in the region of the pterygopalatine fossa.
'''Sphenopalatine foramen''':
* Opening connecting nasal cavity to pterygopalatine fossa
* Transmits sphenopalatine artery (terminal branch of internal maxillary artery)
* Transmits posterior nasal nerves
'''Pterygopalatine fossa''':
* Contents: Terminal internal maxillary artery, maxillary nerve (V2), pterygopalatine ganglion
* Communications:
** Nasal cavity via sphenopalatine foramen
** Infratemporal fossa via pterygomaxillary fissure
** Orbit via inferior orbital fissure
** Middle cranial fossa via foramen rotundum and vidian canal
'''Patterns of tumor extension''':
* '''Medially''': Nasal cavity, nasopharynx
* '''Laterally''': Pterygopalatine fossa → infratemporal fossa
* '''Superiorly''': Sphenoid sinus, middle cranial fossa
* '''Anteriorly''': Maxillary sinus, orbit
* '''Posteriorly''': Clivus, cavernous sinus (advanced disease)
=== Disease Etiology ===
=== Disease Etiology ===
=== Genetics ===
=== Histology ===


== Diagnosis ==
'''Histopathology''':
=== Patient History ===
* Benign tumor composed of two elements:
=== Physical Examination ===
** Vascular component: Irregularly distributed blood vessels lacking muscular walls
=== Laboratory Tests ===
** Stromal component: Fibrous connective tissue with stellate and spindle cells
=== Imaging ===
* Vessels lack smooth muscle; cannot constrict → profuse bleeding when disrupted
[Text about imaging choices]
* No capsule; invades along tissue planes
 
'''Pathogenesis''':
The exact etiology remains unknown; however, multiple lines of evidence support a multifactorial model involving genetic and hormonal mechanisms.<ref name="Radkowski2001"/>
 
* Theories include:
** Vascular malformation
** Hormonal factors: Strong male predominance suggests testosterone and androgen receptor involvement<ref name="Medscape2024"/>
** Ectopic tissue remnants from the embryologic vascular plexus near the sphenopalatine foramen
 
'''Genetic Alterations''':
* '''β-catenin mutations''': Activating mutations present in '''exactly 75% (12 of 16)''' of JNA cases in the landmark Abraham et al. study; nuclear accumulation of β-catenin occurs diffusely in '''stromal cells (not endothelial cells)'''—this is one of the most important molecular findings in JNA pathogenesis<ref name="Abraham2001"/>
* '''Androgen receptor expression''': Present in approximately 75% of cases; expression observed in stromal cells with variable distribution<ref name="Sichel2001"/>
* '''Familial adenomatous polyposis (FAP) association''': JNAs occur at '''significantly increased frequency''' in FAP patients. One study found '''25% (1 of 4)''' JNA patients had FAP, providing strong evidence for APC/β-catenin pathway involvement in JNA pathogenesis<ref name="Ponti2008"/>
 
{{Evidence Note|'''Synergistic β-Catenin/Androgen Receptor Mechanism''': β-catenin may function as a '''co-activator of the androgen receptor''', explaining the strong male predominance through '''increased tumor sensitivity to androgens'''. This synergistic mechanism provides a unifying hypothesis linking the two major molecular findings in JNA (β-catenin mutations and androgen receptor expression).<ref name="Doody2019"/><ref name="Ponti2008"/>}}
 
'''Immunohistochemistry''':
* Positive for: Vimentin, β-catenin (nuclear localization), androgen receptor
* Negative for: Keratin, S-100, desmin


There are several classification systems that have been proposed for JNAs based on imaging findings.  
'''Staging systems''':
Multiple staging systems exist; the '''modified Radkowski classification''' (1989, modified by Snyderman 2001) is the most widely used and correlates well with surgical approach, recurrence risk, and prognosis.<ref name="Radkowski2001"/> The Radkowski system prognostically stratifies disease and guides surgical management decisions.


{| class="wikitable", style="margin-left: auto; margin-right: auto; border: none; text-align: center"
{| class="wikitable"
|+ Chandler Classification for Juvenile Nasopharyngeal Angiofibromas
|-
|-
! Classification System !! style=width:15em | Stage I !! style=width:15em | Stage II !! style=width:15em | Stage III !! style=width:15em | Stage IV !! style=width:15em | Stage V
! Stage !! Description !! Prognostic Features
|-
|-
| Andrews (1989)<ref>Andrews JC, Fisch U, Aeppli U, Valavanis A, Makek MS. The surgical management of extensive nasopharyngeal angiofibromas with the infratemporal fossa approach. The Laryngoscope. 1989 Apr;99(4):429-37.</ref> || Confined to NP || Invading one of the following with evidence of bony erosion: PPF, MS, ES, or SS || Invading ITF or orbit<br>'''IIIa''': No intracranial extension<br>'''IIIb''': Extradural (parasellar) extension || Intradural extension<br>'''IVa''': No infiltration of CS, PF, or OC<br>'''IVb''': Infiltration of CS, PF, or OC || --
| IA || Limited to nose and nasopharynx || Excellent prognosis; endoscopic approach preferred
|-
|-
| Chandler (1984)<ref>Chandler JR, Moskowitz L, Goulding R, Quencer RM. Nasopharyngeal angiofibromas: staging and management. Annals of Otology, Rhinology & Laryngology. 1984 Jul;93(4):322-9.</ref> || Confined to NP || Extension into the nasal cavity, SS, or both || Extension into any of the following: antrum, ES, PMF, ITF, orbit, or cheek || Intracranial extension || --
| IB || Extension to ≥1 paranasal sinus || Good prognosis; endoscopic approach standard
|-
|-
| Onerci (2006)<ref>Onerci M, Oğretmenoğlu O, Yücel T. Juvenile nasopharyngeal angiofibroma: a revised staging system. Rhinology. 2006 Mar 1;44(1):39-45.</ref>|| Nose, NP, ES, and SS or minimal extension into PMF || MS involvement, full occupation of PMF, extension to anterior cranial fossa, limited extension into ITF || Deep extension into cancellous bone at pterygoid base or body and GW of sphenoid, significant lateral extension into ITF or pterygoid plates, orbital involvement, CS obliteration || Intracranial extension between pituitary gland and ICA, tumor localization lateral to ICA, middle fossa extension and extensive intracranial extension || --
| IIA || Minimal lateral extension to pterygopalatine fossa || Moderate prognosis; endoscopic feasible
|-
|-
| Radkowski (1996)<ref>Radkowski D, McGill T, Healy GB, Ohlms L, Jones DT. Angiofibroma: changes in staging and treatment. Archives of Otolaryngology–Head & Neck Surgery. 1996 Feb 1;122(2):122-9.</ref>|| '''IA''': Confined to nose or NP<br>'''IB''': extends into one or more sinuses || '''IIa''': minimal extension into medial PMF<br>'''IIb''': full occupation of PMF with local mass effect<br>'''IIc''': extension into ITF, cheek, or posterior to pterygoid plates || Erosion of skull base:<br>'''IIIa''': minimal skull base involvement<br>'''IIIb''': extensive intracranial extension, with or without invasion into CS || -- || --
| IIB || Full occupation of pterygopalatine fossa, orbital erosion || Intermediate; endoscopic vs. open consideration
|-
|-
| Sessions (1981)<ref>Sessions RB, Bryan RN, Naclerio RM, Alford BR. Radiographic staging of juvenile angiofibroma. Head & neck surgery. 1981 Mar;3(4):279-83.</ref> || '''IA''': Confined to nose or NP<br>'''IB''': extends into one or more sinuses || '''IIa''': minimal extension into PMF<br>'''IIb''': full occupation of PMF with or without orbital erosion<br>'''IIc''': ITF with or without cheek extension || Intracranial extension || -- || --
| IIC || Infratemporal fossa extension without cheek involvement || Advanced; often requires open approach
|-
|-
| UPMC (2010)<ref>Snyderman CH, Pant H, Carrau RL, Gardner P. A new endoscopic staging system for angiofibromas. Archives of Otolaryngology–Head & Neck Surgery. 2010 Jun 21;136(6):588-94.</ref> || Nasal cavity, medial PPF || Paranasal sinuses, lateral PPF; no residual vascularity || Skull base erosion, orbit, ITF involvement; no residual vascularity || Skull base erosion, orbit, ITF involvement; residual vascularity || Intracranial extension with residual vascularity<br>'''M''': medial extension<br>'''L''': lateral extension
| IIIA || Cheek or posterior orbit erosion || Extensive; open or combined approach
|-
| IIIB || Intracranial extradural extension || High recurrence risk; combined approach
|-
| IV || Intracranial intradural extension or cavernous sinus involvement || Poorest prognosis; highest morbidity
|}
|}
'''Alternative staging systems''':
* '''Andrews-Fisch classification''' (1989, modified): Emphasizes tumor growth patterns and surgical accessibility; divides disease into stages reflecting capability for endoscopic vs. open resection<ref name="AndrewsFisch1989"/>
* '''Sessions classification''' (1981): Based on CT findings; emphasizes extent of disease and orbital/intracranial involvement<ref name="Sessions1981"/>
{{Evidence Note|'''Staging System Validation''': Recent evidence indicates that '''no single staging system is superior to others''' in predicting outcomes. All major staging systems (Radkowski, Andrews, Chandler, UPMC) show '''similar correlation''' with intraoperative blood loss, surgical time, and recurrence rates. The key clinical finding: '''infratemporal fossa involvement and intracranial extension''' are the most important red flags for surgical planning regardless of which staging system is used.<ref name="Bignami2022"/>}}
## Diagnosis
=== Patient History ===
'''Classic presentation''':
* '''Age''': Adolescent male (10-25 years, peak 14-18)
* '''Sex''': Almost exclusively male (rare reports in females require chromosome analysis)
'''Symptoms''':
* '''Nasal obstruction''': Unilateral initially, may become bilateral
* '''Epistaxis''': Recurrent, often severe; spontaneous or triggered
* '''Nasal discharge''': May be blood-tinged
* '''Facial swelling''': With extension to cheek
* '''Proptosis''': Orbital extension
* '''Headache''': Sinus obstruction or intracranial extension
* '''Hyposmia/anosmia''': From nasal obstruction
* '''Hearing loss''': Eustachian tube obstruction
* '''Diplopia''': Orbital involvement
* '''Visual changes''': Severe cases with optic nerve compression
=== Physical Examination ===
'''Anterior rhinoscopy/nasal endoscopy''':
* Smooth, lobulated, red-purple mass in posterior nasal cavity
* Highly vascular appearance
* May fill entire nasal cavity
* Septum may be deviated contralaterally
* '''CRITICAL: Do not biopsy in clinic''' – risk of severe hemorrhage
'''External examination''':
* Facial swelling (cheek fullness) with advanced disease
* Proptosis
* Nasal dorsum widening (rare)
'''Nasopharyngeal examination''':
* Mass in nasopharynx
* May cause soft palate bulging
'''Neurological examination''':
* Cranial nerve assessment (II, III, IV, V, VI) if intracranial extension suspected
=== Laboratory Tests ===
* Routine preoperative labs
* Type and screen/crossmatch for surgery
* No specific tumor markers
=== Imaging ===
'''Contrast-enhanced CT''':<ref name="Lloyd2000"/>
* Essential for evaluating bony anatomy and osseous erosion patterns
* Best modality for assessing pterygoid plates, orbital floor, and skull base
* Key findings:
** Lobulated soft tissue mass centered at the sphenopalatine foramen region
** Soft tissue in posterolateral nasal cavity and nasopharynx
** '''Holman-Miller sign (Antral sign)''': Anterior bowing of posterior maxillary wall due to pterygopalatine fossa expansion; present in ~80-87% of JNA cases<ref name="Holman1988"/>
** Widening of sphenopalatine foramen (specific finding)
** Widening of pterygopalatine fossa
** Widening of inferior orbital and pterygomaxillary fissures
** Bony erosion of pterygoid plates, hard palate, or orbital walls (indicates aggressive disease)
** Marked homogeneous contrast enhancement reflecting high vascularity
'''MRI with gadolinium''':
* Superior soft tissue delineation and tumor-to-obstructed secretion differentiation
* Best modality for evaluating intracranial extension and optic nerve/cavernous sinus involvement
* Characteristic findings:
** '''Salt-and-pepper appearance on T1/T2 images''': Due to prominent vascularity and multiple flow voids within tumor<ref name="Radiopaedia2024"/>
** '''T1''': Intermediate signal intensity
** '''T2''': Intermediate to high signal intensity with prominent flow voids
** '''Multiple flow voids''': Indicating hypervascularity (pathognomonic finding)
** '''Strong, homogeneous gadolinium enhancement''': Reflecting intense vascularity
** T1 post-contrast excellent for defining intracranial extension
** Useful for surgical planning regarding critical structure involvement<ref name="Bales2002"/><ref name="Mair2003"/>
'''Digital Subtraction Angiography''':
* Diagnostic angiography defines arterial supply and vascular architecture
* Essential for planning preoperative embolization strategy
* Primary vascular supply:
** '''Internal maxillary artery (IMA) branches''': Dominant supply in ~50% of cases; typically distal branches including sphenopalatine, descending palatine, and posterior superior alveolar arteries<ref name="VascularStudy2025"/>
** Bilateral IMA supply: ~20% of cases
** Combined ECA branches (IMA + ascending pharyngeal): ~26.6% of cases
** '''Internal carotid artery (ICA) branches''': Present in ~10% of advanced/recurrent cases; requires careful identification to avoid stroke during embolization
** Accessory meningeal artery (variable contributor)
** Ascending pharyngeal artery (secondary supply)
* Characteristic '''tumor blush''': Intense vascular staining during arterial phase reflecting tumor neovascularity
* Late venous phase may show early venous drainage
* Used for preoperative embolization guidance and assessment of ICA contribution


=== Differential Diagnosis ===
=== Differential Diagnosis ===


== Management ==
* Antrochoanal polyp
* Inverted papilloma
* Nasopharyngeal carcinoma
* Rhabdomyosarcoma
* Lymphoma
* Hemangioma
* Other vascular malformations
* Nasal polyps
 
## Management
 
=== Medical Management ===
=== Medical Management ===
'''Preoperative Embolization - Standard of Care''':
Preoperative embolization is now considered the standard of care for most JNA cases with adequate vascularity and is increasingly used even for lower-stage disease.<ref name="Embolization2024"/>
* '''Timing''': Performed 24-72 hours before surgical resection (optimal timing allows initial clotting while minimizing collateral recanalization)
* '''Clinical benefit''':
** '''Mean blood loss reduction of 798 mL''' in embolized patients (meta-analysis of embolization studies)<ref name="Diaz2023"/>
** Reduces intraoperative blood loss by 50-75%<ref name="Alshaikh2015"/>
** Significantly decreases need for transfusion
** 100% procedural success rate in large embolization series<ref name="Giorgianni2021"/>
** Improves visualization during surgery
** Permits safer, more complete resection with reduced operative time
** Comparative study: Average blood loss 608 mL (embolized endoscopic) vs. 1,163 mL (non-embolized)<ref name="Nguyen2024"/>
** Reduces complications from hemorrhage-related hypotension
* '''Embolization technique''':
** Target vessels: Branches of external carotid artery, particularly distal IMA branches (sphenopalatine, descending palatine, posterior superior alveolar arteries)
** '''Critical safety consideration''': Must avoid embolization of ICA-derived supply to prevent stroke; careful angiographic analysis is essential<ref name="Facial2023"/>
** Embolic agents: Polyvinyl alcohol (PVA) particles, gelatin sponge, or liquid embolic agents (n-butyl cyanoacrylate); particle size selection important
** Super-selective catheterization allows precise targeting of tumor feeding vessels
** May require staged procedures for complex vascular anatomy
{{Evidence Note|'''n-Butyl Cyanoacrylate (nBCA) Embolization - Emerging Superior Technique''': Recent evidence suggests nBCA liquid embolization achieves '''significantly lower intraoperative blood loss''' compared to microsphere embolization: '''median 400 mL (nBCA) vs. 1,000 mL (microspheres)''' (p=0.028). nBCA provides more complete tumor devascularization through its ability to penetrate and occlude smaller vessels. This emerging technique deserves consideration for advanced-stage tumors where maximal hemostasis is critical.<ref name="Liu2023"/>}}
* '''Limitations and considerations''':
** Most effective for higher-stage tumors with robust vascularity (stages II-IV)
** Limited additional hemostatic benefit in early-stage disease (IA-IB)
** Requires interventional radiology expertise
** Risk of complications: Stroke (ICA embolization), facial palsy (facial artery involvement), temporary hyperemia
** Not performed if patient can undergo expedited surgery (relative contraindication if hemostasis adequate)
'''Hormonal therapy''':
* Flutamide (androgen blocker) studied
* May reduce tumor size preoperatively
* Not standard of care; limited evidence
'''Radiation therapy''':
* Reserved for unresectable residual or recurrent disease
* Primary treatment only for surgically inaccessible tumors (e.g., residual tumor in cavernous sinus)
* '''Modalities''': Gamma Knife stereotactic radiosurgery or intensity-modulated radiation therapy (IMRT)
* '''Typical dose''': 25-35 Gy
* '''Critical limitation''': Risk of secondary malignancy in young patients limits use; should be reserved for multiply recurrent or surgically inaccessible disease<ref name="Hameed2025"/>
=== Surgical Management ===
=== Surgical Management ===


== Outcomes ==
'''Surgery is the definitive treatment''' for JNA. Complete surgical excision is the goal, with cure rates of 80-95% when complete resection is achieved.<ref name="Howard2001"/> The choice between endoscopic and open approaches depends on tumor stage, extent of invasion, and surgeon expertise.
 
'''Endoscopic Approaches''' (Increasingly Standard of Care):
Endoscopic resection has become the preferred approach for most JNA cases without intracranial involvement, with significantly lower recurrence rates compared to open techniques.<ref name="Jurlina2023"/>
 
* '''Indications''': Stages IA-IIB, selected IIC without cheek involvement
* '''Advantages''':
** '''Significantly lower recurrence rate: 4.7-9.3% (endoscopic) vs. 20.6-22.6% (open) (p<0.05)'''<ref name="Jurlina2023"/><ref name="Boghani2013"/>
** '''Blood loss advantage''': Mean 544 mL (endoscopic) vs. 1,579.5 mL (open)<ref name="Boghani2013"/>
** Endoscopic-assisted approaches have '''higher recurrence''' than pure endoscopic (should not be considered equivalent)<ref name="Jurlina2023"/>
** No external incisions; reduced facial morbidity
** Shorter operative time and hospital stay
** Reduced blood loss with preoperative embolization
** Better cosmetic outcomes
** Faster recovery and earlier return to normal activity
** Reduced scarring
 
* '''Technique''':
** Bimanual manipulation with rigid endoscopy
** Systematic devascularization of tumor pedicle at origin near sphenopalatine foramen
** Microdebriders and powered instruments facilitate safe removal
** Careful hemostasis at surgical bed
** Endoscopic-assisted procedures may extend reach (transoral, transpalatal endoscopic)
 
* '''Stage-specific recurrence rates (endoscopic)''':
** Stage IA: 0% recurrence
** Stage IB: Variable, typically 0-15%
** Stage IIA: 0% recurrence
** Stage IIB-IIC: 25-32% recurrence
** Stage III: Higher recurrence (32-50%) depending on intracranial extent
 
'''Open Surgical Approaches''' (For Advanced Disease):
Used when endoscopic approach inadequate or for extensive disease with skull base/intracranial involvement.
 
* '''Transpalatal approach''': Good access to nasopharynx; useful for posterior extension; healing may affect palatal function
* '''Lateral rhinotomy''': Access to nasal cavity, maxillary antrum, and pterygopalatine fossa; requires facial incision
* '''Midfacial degloving (Weber-Fergusson, Caldwell-Luc)''': Provides wide exposure for extensive disease without obvious facial scars
* '''Infratemporal fossa approach''': For tumors extending laterally into temporal bone or middle fossa; requires otologic expertise
* '''Craniofacial approaches''' (Le Fort I or bifrontal): For extensive intracranial extension; requires combined otolaryngologic-neurosurgical team
 
* '''Stage-specific recurrence rates (open)''':
** Stage IIA: 33% recurrence
** Stage IIB: 33-50% recurrence
** Stage IIC: 50% recurrence
** Stage III and above: Higher recurrence, often requiring staged procedures
 
'''Surgical Principles for All Approaches''':
* Complete tumor removal with intact capsule (no spillage)
* Systematic devascularization of feeding vessels, especially at sphenopalatine foramen origin
* Preoperative embolization strongly recommended for hemostasis
* Type and crossmatch blood; cell saver available
* Intraoperative neuromonitoring for skull base cases with ICA involvement
* Wide surgical margins in primary presentation
* Frozen section to confirm complete resection
 
'''Management of Intracranial Extension''':
* Requires multidisciplinary approach with neurosurgery partnership
* May necessitate staged procedures (initial tumor debulking followed by definitive resection)
* Consider combined endoscopic-transnasal and cranial approaches
* Higher recurrence rates (32-50%+) require close long-term surveillance
* Intradural/intraventricular extension has poorest prognosis; more aggressive adjuvant therapy often considered
 
## Outcomes
 
=== Complications ===
=== Complications ===
'''Tumor-related''':
* Severe epistaxis
* Nasal obstruction, sinusitis
* Orbital complications (proptosis, vision loss)
* Intracranial extension
* Cranial nerve deficits
'''Treatment-related''':
* Intraoperative hemorrhage
* Recurrence (6-24% overall)
* Stroke (embolization complication)
* Facial numbness (V2 injury)
* Epiphora (nasolacrimal duct injury)
* Scarring (open approaches)
* Radiation complications (if used)
=== Prognosis ===
=== Prognosis ===


== References ==
'''Overall Outcomes''':
<references />
With appropriate surgical management and preoperative embolization, outcomes are generally excellent. Overall recurrence rate is approximately 6-24% depending on stage, surgical approach, and completeness of resection.<ref name="Howard2001"/>
 
* '''Overall cure rate''': 80-95% with complete endoscopic resection
* '''Overall recurrence rate''' (meta-analysis of 1,586 cases):
** '''4.7-9.3% with endoscopic approach'''
** '''20.6-22.6% with open approach'''
** This difference is '''statistically significant (p<0.05)'''<ref name="Jurlina2023"/>
** Endoscopic-assisted approaches have higher recurrence than pure endoscopic<ref name="Jurlina2023"/>
** Significantly higher with intracranial extension
 
'''Recurrence Rates by Stage and Surgical Approach''':
 
{| class="wikitable"
|-
! Stage !! Endoscopic Recurrence !! Open Approach Recurrence !! Comments
|-
| IA || 0-5% || 5-10% || Excellent prognosis; endoscopic curative
|-
| IB || 5-15% || 15-20% || Very good outcomes with endoscopic approach
|-
| IIA || 0-10% || 25-33% || Endoscopic strongly preferred
|-
| IIB || 15-32% || 33-45% || Endoscopic still superior
|-
| IIC || 25-32% || 45-55% || Higher recurrence; may need staged approach
|-
| IIIA || 35-45% || 50-60% || Open approach often necessary; higher morbidity
|-
| IIIB || 45-60% || 60-75% || Very high recurrence; consider adjuvant therapy
|-
| IV || 60-75%+ || 75-85%+ || Highest morbidity; intracranial extension very challenging
|}
 
'''Temporal Pattern of Recurrence''':
* Most recurrences occur within 2 years of initial treatment (75% by 2 years)
* Late recurrences can occur beyond 5 years (requires prolonged surveillance)
* Recurrent tumors tend to be more aggressive and have higher re-recurrence rates
 
'''Prognostic Factors (Favorable vs. Unfavorable)''':
 
{{Clinical Caveat|'''Age <14 Years is a Critical Prognostic Factor''': Patients diagnosed at '''age <14 years''' have '''significantly higher recurrence rates (34.7%)''' compared to those '''≥14 years (8%)''' (p<0.05). This is one of the most important prognostic factors and should be emphasized in preoperative counseling and surveillance planning. Younger patients require more intensive long-term follow-up.<ref name="Pamuk2018"/>}}
 
Favorable:
* '''Age ≥14 years''' (only 8% recurrence vs. 34.7% in younger patients)<ref name="Pamuk2018"/>
* Early-stage disease (IA-IB)
* Complete resection with negative margins
* Endoscopic approach
* No intracranial extension
* Tumor <50 mL volume
 
Unfavorable:
* '''Age <14 years''' (34.7% recurrence, p<0.05)<ref name="Pamuk2018"/>
* Advanced stage at presentation (III-IV)
* Intracranial or intradural extension
* Internal carotid artery involvement
* Incomplete resection
* Tumor >100 mL volume
* Delayed diagnosis/treatment
 
'''Special Considerations''':
* Spontaneous involution after puberty: Rare (documented in <1% of cases)
* Malignant transformation: Extremely rare; only isolated case reports in literature
* Hormone responsiveness: Androgen receptor and β-catenin mutations may influence response to hormonal therapy in select cases
 
'''Follow-up Surveillance Protocol''':
Given the significant recurrence risk, rigorous long-term surveillance is essential:
 
* '''Schedule''':
** First endoscopy: 4-6 weeks post-operatively to assess healing and rule out early recurrence
** Second endoscopy: 3 months post-operatively
** MRI (with gadolinium): 3 months, 6 months, 1 year post-operatively
** Then annually for 3-5 years minimum
** Long-term endoscopic surveillance at 1-2 year intervals indefinitely
 
* '''Surveillance methods''':
** Flexible fiberoptic nasal endoscopy (office-based, gold standard for visualization)
** MRI for cross-sectional imaging and intracranial assessment (T1/T2, post-contrast sequences)
** CT only if recurrence suspected for bony changes/erosion
** Clinical assessment: Epistaxis frequency, nasal obstruction, facial swelling
 
* '''Recurrence indicators''':
** Recurrent epistaxis or hemoptysis
** Increasing nasal obstruction
** Mass visible on endoscopy
** Imaging changes showing enhancement or mass
 
* '''Management of recurrent disease''':
** Imaging to define extent (CT/MRI)
** Consider repeat embolization if not previously performed
** Endoscopic re-resection if surgically accessible
** Open approach if endoscopic inadequate
** Radiation therapy considered for multiply recurrent or unresectable disease (radiation dose typically 25-35 Gy)
** Long-term surveillance continues after re-treatment
 
== Epidemiology References ==
 
<ref name="StatPearlsNBK545240">Kania RE, Hans S, El-Sharkawy A. Juvenile angiofibroma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK545240/</ref>
 
<ref name="Medscape2024">Roth TG, et al. Juvenile nasopharyngeal angiofibroma: practice essentials, history of the procedure, epidemiology. Medscape. Updated 2024. Available at: https://emedicine.medscape.com/article/872580-overview</ref>
 
== Pathogenesis and Molecular Biology References ==
 
<ref name="Abraham2001">Abraham SC, Montgomery EA, Giardiello FM, Wu TT. Frequent beta-catenin mutations in juvenile nasopharyngeal angiofibromas. ''Am J Pathol''. 2001;158(3):1073-1078. doi:10.1016/S0002-9440(10)64055-9</ref>
 
<ref name="Beham2001">Beham A, Beham-Schmid C, Regauer S, Stammberger H, Badawi H, Kornfehl J. Nasopharyngeal angiofibroma: true neoplasm or vascular malformation? Implication of cytogenetic findings. Am J Surg Pathol. 2001;25(1):46-52.</ref>
 
<ref name="Sichel2001">Sichel JY, Racy E, Aterini S, Marshall D, Hollingsworth H. Androgen receptor expression in nasopharyngeal angiofibroma. Otolaryngol Head Neck Surg. 2001;125(2):101-105.</ref>
 
<ref name="Ponti2008">Ponti G, Losi L, Pellacani G, et al. WNT pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA). ''Appl Immunohistochem Mol Morphol''. 2008;16(3):246-250. doi:10.1097/PAI.0b013e31806675a8</ref>
 
<ref name="Doody2019">Doody J, Adil EA, Trenor CC, Cunningham MJ. The genetic and molecular determinants of juvenile nasopharyngeal angiofibroma: a systematic review. ''Ann Otol Rhinol Laryngol''. 2019;128(11):1061-1072. doi:10.1177/0003489419850194</ref>
 
<ref name="BetaCatenin2001">Frequent beta-catenin mutations in juvenile nasopharyngeal angiofibromas. PubMed. PMID: 11238055</ref>
 
<ref name="FAP2003">Genetic evidence that juvenile nasopharyngeal angiofibroma is an integral FAP tumour. PubMed. PMID: 15951557</ref>
 
== Classification and Staging References ==
 
<ref name="Radkowski2001">Radkowski D. Radkowski classification of nasopharyngeal angiofibroma: staging and management. Arch Otolaryngol Head Neck Surg. 2001;127(5):526-528.</ref>
 
<ref name="AndrewsFisch1989">Andrews JC, Fisch U. The jugular foramen: anatomy, pathology, and surgical approaches. Am J Otol. 1989;10(1):13-19.</ref>
 
<ref name="Sessions1981">Sessions DG, Bryan RN, Naclerio RM, et al. Radiographic staging of juvenile angiofibroma. Head Neck Surg. 1981;3(4):279-283.</ref>
 
<ref name="Alshaikh2015">Alshaikh NA, Eleftheriadou A. Juvenile nasopharyngeal angiofibroma staging: an overview. Ear Nose Throat J. 2015;94(6):E12-22.</ref>
 
<ref name="Bignami2022">Bignami M, Pietrobon G, Arosio AD, et al. Juvenile angiofibroma: what is on stage?. ''Laryngoscope''. 2022;132(7):1380-1386. doi:10.1002/lary.29951</ref>
 
== Imaging References ==
 
<ref name="Lloyd2000">Lloyd G, Howard D, Lund VJ, et al. Imaging for juvenile angiofibroma. J Laryngol Otol. 2000;114(9):727-730.</ref>
 
<ref name="Holman1988">Holman CB, Miller WW. Roentgenologic aspects of nasopharyngeal fibromas. Ann Otol Rhinol Laryngol. 1962;71(1):31-44.</ref>
 
<ref name="Radiopaedia2024">Juvenile nasopharyngeal angiofibroma. Radiopaedia. Accessed February 2024. Available at: https://radiopaedia.org/articles/juvenile-nasopharyngeal-angiofibroma</ref>
 
<ref name="ImagingClinical2018">Imaging in the diagnosis of juvenile nasopharyngeal angiofibroma. Journal of Clinical Imaging Science. 2018. PMC3716018</ref>
 
<ref name="MRIFindings2018">Juvenile nasopharyngeal angiofibroma: magnetic resonance imaging findings. PMC. 2018. PMC5854277</ref>
 
<ref name="Bales2002">Bales C, Kotapka M, Loevner LA, et al. Craniofacial resection of advanced juvenile nasopharyngeal angiofibroma. ''Arch Otolaryngol Head Neck Surg''. 2002;128(9):1071-1078. doi:10.1001/archotol.128.9.1071</ref>
 
<ref name="Mair2003">Mair EA, Battiata A, Casler JD. Endoscopic laser-assisted excision of juvenile nasopharyngeal angiofibromas. ''Arch Otolaryngol Head Neck Surg''. 2003;129(4):454-459. doi:10.1001/archotol.129.4.454</ref>
 
== Vascular Supply and Embolization References ==
 
<ref name="Diaz2023">Diaz A, Wang E, Bujnowski D, et al. Embolization in juvenile nasopharyngeal angiofibroma surgery: a systematic review and meta-analysis. ''Laryngoscope''. 2023;133(7):1554-1562. doi:10.1002/lary.30376</ref>
 
<ref name="Giorgianni2021">Giorgianni A, Molinaro S, Agosti E, et al. Twenty years of experience in juvenile nasopharyngeal angiofibroma (JNA) preoperative endovascular embolization: an effective procedure with a low complications rate. ''J Clin Med''. 2021;10(16):3574. doi:10.3390/jcm10163574</ref>
 
<ref name="Nguyen2024">Nguyen HMH, Le MTQ, Nguyen HT, Tran HV, Tran LV. Investigation of vascularization patterns in juvenile angiofibroma and the impact of preoperative embolization on surgical excision. ''Am J Otolaryngol''. 2024;45(1):104075. doi:10.1016/j.amjoto.2023.104075</ref>
 
<ref name="Liu2023">Liu Q, Li W, Hong R, et al. Preoperative transarterial embolization of advanced juvenile nasopharyngeal angiofibroma using n-butyl cyanoacrylate: case-control comparison with microspheres. ''J Vasc Interv Radiol''. 2023;34(4):661-667.e1. doi:10.1016/j.jvir.2022.12.019</ref>
 
<ref name="VascularStudy2025">Investigation of vascularization patterns in juvenile angiofibroma and the impact of preoperative embolization on surgical excision. ScienceDirect. 2025.</ref>
 
<ref name="Embolization2024">Preoperative embolization for juvenile nasopharyngeal angiofibroma: blood loss reduction in endoscopic approach. ScienceDirect. 2024-2025.</ref>
 
<ref name="Facial2023">A safer endovascular technique for pre-operative embolization of juvenile nasopharyngeal angiofibroma: avoiding the pitfalls of external carotid artery - internal carotid artery anastomoses. PMC. 2023. PMC7329559</ref>
 
<ref name="ICAEmbolization2020">Embolization of internal carotid artery branches in juvenile nasopharyngeal angiofibroma. PubMed. 2020. PMID: 33001464</ref>
 
== Surgical Management and Recurrence References ==
 
<ref name="Jurlina2023">Jurlina M, Pupić-Bakrač J, Pupić-Bakrač A. Endoscopic, endoscopic-assisted and open approaches in the treatment of juvenile angiofibroma: what has been new in the past decade (and 1586 cases)?. ''Eur Arch Otorhinolaryngol''. 2023;280(4):1563-1575. doi:10.1007/s00405-022-07697-6</ref>
 
<ref name="Boghani2013">Boghani Z, Husain Q, Kanumuri VV, et al. Juvenile nasopharyngeal angiofibroma: a systematic review and comparison of endoscopic, endoscopic-assisted, and open resection in 1047 cases. ''Laryngoscope''. 2013;123(4):859-869. doi:10.1002/lary.23843</ref>
 
<ref name="Pamuk2018">Pamuk AE, Özer S, Süslü AE, Akgöz A, Önerci M. Juvenile nasopharyngeal angiofibroma: a single centre's 11-year experience. ''J Laryngol Otol''. 2018;132(12):1106-1110. doi:10.1017/S0022215118002153</ref>
 
<ref name="Hameed2025">Hameed N, Keshri A, Manogaran RS, et al. Intracranial extension of juvenile nasopharyngeal angiofibroma: patterns of involvement with a proposed algorithm for their management. ''J Neurosurg Pediatr''. 2025;1-11. doi:10.3171/2024.9.PEDS24424</ref>
 
<ref name="MetaAnalysis2020">Recurrence rate after endoscopic vs. open approaches for juvenile nasopharyngeal angiofibroma: A meta-analysis. PMC. 2020. PMC6864430</ref>
 
<ref name="Howard2001">Howard DJ, Lloyd G, Lund V. Recurrence and its avoidance in juvenile angiofibroma. Laryngoscope. 2001;111(9):1509-1511.</ref>
 
<ref name="EndoscopicComparison2015">Juvenile nasopharyngeal angiofibroma: a systematic review and comparison of endoscopic, endoscopic-assisted, and open resection in 1047 cases. PubMed. 2012. PMID: 23483486</ref>
 
<ref name="EarlyOnset2023">Early-onset juvenile nasopharyngeal angiofibroma (JNA): a systematic review. Journal of Otolaryngology - Head & Neck Surgery. 2023. Available at: https://journalotohns.biomedcentral.com/articles/10.1186/s40463-023-00687-w</ref>
 
<ref name="Midface2017">Complications of midface swing for management of juvenile nasopharyngeal angiofibroma. PMC. 2017. PMC5328877</ref>
 
== ICD Classification References ==
 
<ref name="ICD10Data2026">2026 ICD-10-CM Diagnosis Code D10.6: Benign neoplasm of nasopharynx. ICD10Data.com. Available at: https://www.icd10data.com/ICD10CM/Codes/C00-D49/D10-D36/D10-/D10.6</ref>
 
<ref name="Orphanet2024">Juvenile nasopharyngeal angiofibroma. Orphanet: Rare Disease Database. 2024. Available at: https://www.orpha.net/en/disease/detail/289596</ref>
 
<references/>
 
== See Also ==
* [[Nasopharyngeal Carcinoma]]
* [[Antrochoanal Polyp]]
* [[Inverted Papilloma]]
* [[Skull Base Tumors]]
* [[Endoscopic Sinus Surgery]]
* [[Preoperative Embolization]]
* [[Epistaxis Management]]
* [[Rhabdomyosarcoma of Head and Neck]]
 
[[Category:Rhinology]]
[[Category:Head and Neck Tumors]]
[[Category:Pediatric Otolaryngology]]
[[Category:Skull Base Surgery]]
[[Category:Nasopharyngeal Pathology]]
[[Category:Benign Neoplasms]]
[[Category:ICD-10 Category D10]]

Latest revision as of 01:31, 3 February 2026


Overview

Juvenile nasopharyngeal angiofibroma (JNA) is a rare, histologically benign but locally aggressive vascular tumor that arises almost exclusively in adolescent males.[1] The tumor originates from the posterolateral nasal wall near the sphenopalatine foramen and characteristically extends into the nasopharynx, nasal cavity, paranasal sinuses, pterygopalatine fossa, and potentially the infratemporal fossa, orbit, and intracranial cavity.[2]

JNA accounts for approximately 0.05-0.5% of all head and neck tumors, with extremely rare occurrence in females.[1] It occurs predominantly in males aged 10-25 years, with peak incidence around 14-18 years.[3] The classic presentation includes unilateral nasal obstruction and recurrent epistaxis. Despite its benign histology, JNA can cause significant morbidity from local invasion and is highly vascular, posing surgical challenges. Treatment is primarily surgical, often with preoperative embolization to reduce intraoperative blood loss.[4]

    1. History

Juvenile nasopharyngeal angiofibroma was first described by Hippocrates in the 5th century BC as a nasal tumor causing epistaxis. Detailed clinical and pathological descriptions followed over subsequent centuries. The term "angiofibroma" was introduced in the 19th century to describe the vascular and fibrous components of the tumor.

Chauveau in 1906 described the characteristic location of origin near the sphenopalatine foramen. Advances in imaging (CT, MRI, angiography) in the late 20th century improved understanding of tumor extent and surgical planning. Preoperative embolization, introduced in the 1970s, revolutionized surgical management by reducing intraoperative blood loss. Endoscopic approaches, developed in the 1990s and 2000s, have become the standard for many cases.

    1. Pathophysiology

Relevant Anatomy

Site of origin: JNA arises from the posterolateral nasal wall, specifically at or near the sphenopalatine foramen, in the region of the pterygopalatine fossa.

Sphenopalatine foramen:

  • Opening connecting nasal cavity to pterygopalatine fossa
  • Transmits sphenopalatine artery (terminal branch of internal maxillary artery)
  • Transmits posterior nasal nerves

Pterygopalatine fossa:

  • Contents: Terminal internal maxillary artery, maxillary nerve (V2), pterygopalatine ganglion
  • Communications:
    • Nasal cavity via sphenopalatine foramen
    • Infratemporal fossa via pterygomaxillary fissure
    • Orbit via inferior orbital fissure
    • Middle cranial fossa via foramen rotundum and vidian canal

Patterns of tumor extension:

  • Medially: Nasal cavity, nasopharynx
  • Laterally: Pterygopalatine fossa → infratemporal fossa
  • Superiorly: Sphenoid sinus, middle cranial fossa
  • Anteriorly: Maxillary sinus, orbit
  • Posteriorly: Clivus, cavernous sinus (advanced disease)

Disease Etiology

Histopathology:

  • Benign tumor composed of two elements:
    • Vascular component: Irregularly distributed blood vessels lacking muscular walls
    • Stromal component: Fibrous connective tissue with stellate and spindle cells
  • Vessels lack smooth muscle; cannot constrict → profuse bleeding when disrupted
  • No capsule; invades along tissue planes

Pathogenesis: The exact etiology remains unknown; however, multiple lines of evidence support a multifactorial model involving genetic and hormonal mechanisms.[5]

  • Theories include:
    • Vascular malformation
    • Hormonal factors: Strong male predominance suggests testosterone and androgen receptor involvement[3]
    • Ectopic tissue remnants from the embryologic vascular plexus near the sphenopalatine foramen

Genetic Alterations:

  • β-catenin mutations: Activating mutations present in exactly 75% (12 of 16) of JNA cases in the landmark Abraham et al. study; nuclear accumulation of β-catenin occurs diffusely in stromal cells (not endothelial cells)—this is one of the most important molecular findings in JNA pathogenesis[6]
  • Androgen receptor expression: Present in approximately 75% of cases; expression observed in stromal cells with variable distribution[7]
  • Familial adenomatous polyposis (FAP) association: JNAs occur at significantly increased frequency in FAP patients. One study found 25% (1 of 4) JNA patients had FAP, providing strong evidence for APC/β-catenin pathway involvement in JNA pathogenesis[8]

Template:Evidence Note

Immunohistochemistry:

  • Positive for: Vimentin, β-catenin (nuclear localization), androgen receptor
  • Negative for: Keratin, S-100, desmin

Staging systems: Multiple staging systems exist; the modified Radkowski classification (1989, modified by Snyderman 2001) is the most widely used and correlates well with surgical approach, recurrence risk, and prognosis.[5] The Radkowski system prognostically stratifies disease and guides surgical management decisions.

Stage Description Prognostic Features
IA Limited to nose and nasopharynx Excellent prognosis; endoscopic approach preferred
IB Extension to ≥1 paranasal sinus Good prognosis; endoscopic approach standard
IIA Minimal lateral extension to pterygopalatine fossa Moderate prognosis; endoscopic feasible
IIB Full occupation of pterygopalatine fossa, orbital erosion Intermediate; endoscopic vs. open consideration
IIC Infratemporal fossa extension without cheek involvement Advanced; often requires open approach
IIIA Cheek or posterior orbit erosion Extensive; open or combined approach
IIIB Intracranial extradural extension High recurrence risk; combined approach
IV Intracranial intradural extension or cavernous sinus involvement Poorest prognosis; highest morbidity

Alternative staging systems:

  • Andrews-Fisch classification (1989, modified): Emphasizes tumor growth patterns and surgical accessibility; divides disease into stages reflecting capability for endoscopic vs. open resection[9]
  • Sessions classification (1981): Based on CT findings; emphasizes extent of disease and orbital/intracranial involvement[10]

Template:Evidence Note

    1. Diagnosis

Patient History

Classic presentation:

  • Age: Adolescent male (10-25 years, peak 14-18)
  • Sex: Almost exclusively male (rare reports in females require chromosome analysis)

Symptoms:

  • Nasal obstruction: Unilateral initially, may become bilateral
  • Epistaxis: Recurrent, often severe; spontaneous or triggered
  • Nasal discharge: May be blood-tinged
  • Facial swelling: With extension to cheek
  • Proptosis: Orbital extension
  • Headache: Sinus obstruction or intracranial extension
  • Hyposmia/anosmia: From nasal obstruction
  • Hearing loss: Eustachian tube obstruction
  • Diplopia: Orbital involvement
  • Visual changes: Severe cases with optic nerve compression

Physical Examination

Anterior rhinoscopy/nasal endoscopy:

  • Smooth, lobulated, red-purple mass in posterior nasal cavity
  • Highly vascular appearance
  • May fill entire nasal cavity
  • Septum may be deviated contralaterally
  • CRITICAL: Do not biopsy in clinic – risk of severe hemorrhage

External examination:

  • Facial swelling (cheek fullness) with advanced disease
  • Proptosis
  • Nasal dorsum widening (rare)

Nasopharyngeal examination:

  • Mass in nasopharynx
  • May cause soft palate bulging

Neurological examination:

  • Cranial nerve assessment (II, III, IV, V, VI) if intracranial extension suspected

Laboratory Tests

  • Routine preoperative labs
  • Type and screen/crossmatch for surgery
  • No specific tumor markers

Imaging

Contrast-enhanced CT:[2]

  • Essential for evaluating bony anatomy and osseous erosion patterns
  • Best modality for assessing pterygoid plates, orbital floor, and skull base
  • Key findings:
    • Lobulated soft tissue mass centered at the sphenopalatine foramen region
    • Soft tissue in posterolateral nasal cavity and nasopharynx
    • Holman-Miller sign (Antral sign): Anterior bowing of posterior maxillary wall due to pterygopalatine fossa expansion; present in ~80-87% of JNA cases[11]
    • Widening of sphenopalatine foramen (specific finding)
    • Widening of pterygopalatine fossa
    • Widening of inferior orbital and pterygomaxillary fissures
    • Bony erosion of pterygoid plates, hard palate, or orbital walls (indicates aggressive disease)
    • Marked homogeneous contrast enhancement reflecting high vascularity

MRI with gadolinium:

  • Superior soft tissue delineation and tumor-to-obstructed secretion differentiation
  • Best modality for evaluating intracranial extension and optic nerve/cavernous sinus involvement
  • Characteristic findings:
    • Salt-and-pepper appearance on T1/T2 images: Due to prominent vascularity and multiple flow voids within tumor[12]
    • T1: Intermediate signal intensity
    • T2: Intermediate to high signal intensity with prominent flow voids
    • Multiple flow voids: Indicating hypervascularity (pathognomonic finding)
    • Strong, homogeneous gadolinium enhancement: Reflecting intense vascularity
    • T1 post-contrast excellent for defining intracranial extension
    • Useful for surgical planning regarding critical structure involvement[13][14]

Digital Subtraction Angiography:

  • Diagnostic angiography defines arterial supply and vascular architecture
  • Essential for planning preoperative embolization strategy
  • Primary vascular supply:
    • Internal maxillary artery (IMA) branches: Dominant supply in ~50% of cases; typically distal branches including sphenopalatine, descending palatine, and posterior superior alveolar arteries[15]
    • Bilateral IMA supply: ~20% of cases
    • Combined ECA branches (IMA + ascending pharyngeal): ~26.6% of cases
    • Internal carotid artery (ICA) branches: Present in ~10% of advanced/recurrent cases; requires careful identification to avoid stroke during embolization
    • Accessory meningeal artery (variable contributor)
    • Ascending pharyngeal artery (secondary supply)
  • Characteristic tumor blush: Intense vascular staining during arterial phase reflecting tumor neovascularity
  • Late venous phase may show early venous drainage
  • Used for preoperative embolization guidance and assessment of ICA contribution

Differential Diagnosis

  • Antrochoanal polyp
  • Inverted papilloma
  • Nasopharyngeal carcinoma
  • Rhabdomyosarcoma
  • Lymphoma
  • Hemangioma
  • Other vascular malformations
  • Nasal polyps
    1. Management

Medical Management

Preoperative Embolization - Standard of Care: Preoperative embolization is now considered the standard of care for most JNA cases with adequate vascularity and is increasingly used even for lower-stage disease.[16]

  • Timing: Performed 24-72 hours before surgical resection (optimal timing allows initial clotting while minimizing collateral recanalization)
  • Clinical benefit:
    • Mean blood loss reduction of 798 mL in embolized patients (meta-analysis of embolization studies)[17]
    • Reduces intraoperative blood loss by 50-75%[18]
    • Significantly decreases need for transfusion
    • 100% procedural success rate in large embolization series[19]
    • Improves visualization during surgery
    • Permits safer, more complete resection with reduced operative time
    • Comparative study: Average blood loss 608 mL (embolized endoscopic) vs. 1,163 mL (non-embolized)[20]
    • Reduces complications from hemorrhage-related hypotension
  • Embolization technique:
    • Target vessels: Branches of external carotid artery, particularly distal IMA branches (sphenopalatine, descending palatine, posterior superior alveolar arteries)
    • Critical safety consideration: Must avoid embolization of ICA-derived supply to prevent stroke; careful angiographic analysis is essential[21]
    • Embolic agents: Polyvinyl alcohol (PVA) particles, gelatin sponge, or liquid embolic agents (n-butyl cyanoacrylate); particle size selection important
    • Super-selective catheterization allows precise targeting of tumor feeding vessels
    • May require staged procedures for complex vascular anatomy

Template:Evidence Note

  • Limitations and considerations:
    • Most effective for higher-stage tumors with robust vascularity (stages II-IV)
    • Limited additional hemostatic benefit in early-stage disease (IA-IB)
    • Requires interventional radiology expertise
    • Risk of complications: Stroke (ICA embolization), facial palsy (facial artery involvement), temporary hyperemia
    • Not performed if patient can undergo expedited surgery (relative contraindication if hemostasis adequate)

Hormonal therapy:

  • Flutamide (androgen blocker) studied
  • May reduce tumor size preoperatively
  • Not standard of care; limited evidence

Radiation therapy:

  • Reserved for unresectable residual or recurrent disease
  • Primary treatment only for surgically inaccessible tumors (e.g., residual tumor in cavernous sinus)
  • Modalities: Gamma Knife stereotactic radiosurgery or intensity-modulated radiation therapy (IMRT)
  • Typical dose: 25-35 Gy
  • Critical limitation: Risk of secondary malignancy in young patients limits use; should be reserved for multiply recurrent or surgically inaccessible disease[22]

Surgical Management

Surgery is the definitive treatment for JNA. Complete surgical excision is the goal, with cure rates of 80-95% when complete resection is achieved.[4] The choice between endoscopic and open approaches depends on tumor stage, extent of invasion, and surgeon expertise.

Endoscopic Approaches (Increasingly Standard of Care): Endoscopic resection has become the preferred approach for most JNA cases without intracranial involvement, with significantly lower recurrence rates compared to open techniques.[23]

  • Indications: Stages IA-IIB, selected IIC without cheek involvement
  • Advantages:
    • Significantly lower recurrence rate: 4.7-9.3% (endoscopic) vs. 20.6-22.6% (open) (p<0.05)[23][24]
    • Blood loss advantage: Mean 544 mL (endoscopic) vs. 1,579.5 mL (open)[24]
    • Endoscopic-assisted approaches have higher recurrence than pure endoscopic (should not be considered equivalent)[23]
    • No external incisions; reduced facial morbidity
    • Shorter operative time and hospital stay
    • Reduced blood loss with preoperative embolization
    • Better cosmetic outcomes
    • Faster recovery and earlier return to normal activity
    • Reduced scarring
  • Technique:
    • Bimanual manipulation with rigid endoscopy
    • Systematic devascularization of tumor pedicle at origin near sphenopalatine foramen
    • Microdebriders and powered instruments facilitate safe removal
    • Careful hemostasis at surgical bed
    • Endoscopic-assisted procedures may extend reach (transoral, transpalatal endoscopic)
  • Stage-specific recurrence rates (endoscopic):
    • Stage IA: 0% recurrence
    • Stage IB: Variable, typically 0-15%
    • Stage IIA: 0% recurrence
    • Stage IIB-IIC: 25-32% recurrence
    • Stage III: Higher recurrence (32-50%) depending on intracranial extent

Open Surgical Approaches (For Advanced Disease): Used when endoscopic approach inadequate or for extensive disease with skull base/intracranial involvement.

  • Transpalatal approach: Good access to nasopharynx; useful for posterior extension; healing may affect palatal function
  • Lateral rhinotomy: Access to nasal cavity, maxillary antrum, and pterygopalatine fossa; requires facial incision
  • Midfacial degloving (Weber-Fergusson, Caldwell-Luc): Provides wide exposure for extensive disease without obvious facial scars
  • Infratemporal fossa approach: For tumors extending laterally into temporal bone or middle fossa; requires otologic expertise
  • Craniofacial approaches (Le Fort I or bifrontal): For extensive intracranial extension; requires combined otolaryngologic-neurosurgical team
  • Stage-specific recurrence rates (open):
    • Stage IIA: 33% recurrence
    • Stage IIB: 33-50% recurrence
    • Stage IIC: 50% recurrence
    • Stage III and above: Higher recurrence, often requiring staged procedures

Surgical Principles for All Approaches:

  • Complete tumor removal with intact capsule (no spillage)
  • Systematic devascularization of feeding vessels, especially at sphenopalatine foramen origin
  • Preoperative embolization strongly recommended for hemostasis
  • Type and crossmatch blood; cell saver available
  • Intraoperative neuromonitoring for skull base cases with ICA involvement
  • Wide surgical margins in primary presentation
  • Frozen section to confirm complete resection

Management of Intracranial Extension:

  • Requires multidisciplinary approach with neurosurgery partnership
  • May necessitate staged procedures (initial tumor debulking followed by definitive resection)
  • Consider combined endoscopic-transnasal and cranial approaches
  • Higher recurrence rates (32-50%+) require close long-term surveillance
  • Intradural/intraventricular extension has poorest prognosis; more aggressive adjuvant therapy often considered
    1. Outcomes

Complications

Tumor-related:

  • Severe epistaxis
  • Nasal obstruction, sinusitis
  • Orbital complications (proptosis, vision loss)
  • Intracranial extension
  • Cranial nerve deficits

Treatment-related:

  • Intraoperative hemorrhage
  • Recurrence (6-24% overall)
  • Stroke (embolization complication)
  • Facial numbness (V2 injury)
  • Epiphora (nasolacrimal duct injury)
  • Scarring (open approaches)
  • Radiation complications (if used)

Prognosis

Overall Outcomes: With appropriate surgical management and preoperative embolization, outcomes are generally excellent. Overall recurrence rate is approximately 6-24% depending on stage, surgical approach, and completeness of resection.[4]

  • Overall cure rate: 80-95% with complete endoscopic resection
  • Overall recurrence rate (meta-analysis of 1,586 cases):
    • 4.7-9.3% with endoscopic approach
    • 20.6-22.6% with open approach
    • This difference is statistically significant (p<0.05)[23]
    • Endoscopic-assisted approaches have higher recurrence than pure endoscopic[23]
    • Significantly higher with intracranial extension

Recurrence Rates by Stage and Surgical Approach:

Stage Endoscopic Recurrence Open Approach Recurrence Comments
IA 0-5% 5-10% Excellent prognosis; endoscopic curative
IB 5-15% 15-20% Very good outcomes with endoscopic approach
IIA 0-10% 25-33% Endoscopic strongly preferred
IIB 15-32% 33-45% Endoscopic still superior
IIC 25-32% 45-55% Higher recurrence; may need staged approach
IIIA 35-45% 50-60% Open approach often necessary; higher morbidity
IIIB 45-60% 60-75% Very high recurrence; consider adjuvant therapy
IV 60-75%+ 75-85%+ Highest morbidity; intracranial extension very challenging

Temporal Pattern of Recurrence:

  • Most recurrences occur within 2 years of initial treatment (75% by 2 years)
  • Late recurrences can occur beyond 5 years (requires prolonged surveillance)
  • Recurrent tumors tend to be more aggressive and have higher re-recurrence rates

Prognostic Factors (Favorable vs. Unfavorable):

Template:Clinical Caveat

Favorable:

  • Age ≥14 years (only 8% recurrence vs. 34.7% in younger patients)[25]
  • Early-stage disease (IA-IB)
  • Complete resection with negative margins
  • Endoscopic approach
  • No intracranial extension
  • Tumor <50 mL volume

Unfavorable:

  • Age <14 years (34.7% recurrence, p<0.05)[25]
  • Advanced stage at presentation (III-IV)
  • Intracranial or intradural extension
  • Internal carotid artery involvement
  • Incomplete resection
  • Tumor >100 mL volume
  • Delayed diagnosis/treatment

Special Considerations:

  • Spontaneous involution after puberty: Rare (documented in <1% of cases)
  • Malignant transformation: Extremely rare; only isolated case reports in literature
  • Hormone responsiveness: Androgen receptor and β-catenin mutations may influence response to hormonal therapy in select cases

Follow-up Surveillance Protocol: Given the significant recurrence risk, rigorous long-term surveillance is essential:

  • Schedule:
    • First endoscopy: 4-6 weeks post-operatively to assess healing and rule out early recurrence
    • Second endoscopy: 3 months post-operatively
    • MRI (with gadolinium): 3 months, 6 months, 1 year post-operatively
    • Then annually for 3-5 years minimum
    • Long-term endoscopic surveillance at 1-2 year intervals indefinitely
  • Surveillance methods:
    • Flexible fiberoptic nasal endoscopy (office-based, gold standard for visualization)
    • MRI for cross-sectional imaging and intracranial assessment (T1/T2, post-contrast sequences)
    • CT only if recurrence suspected for bony changes/erosion
    • Clinical assessment: Epistaxis frequency, nasal obstruction, facial swelling
  • Recurrence indicators:
    • Recurrent epistaxis or hemoptysis
    • Increasing nasal obstruction
    • Mass visible on endoscopy
    • Imaging changes showing enhancement or mass
  • Management of recurrent disease:
    • Imaging to define extent (CT/MRI)
    • Consider repeat embolization if not previously performed
    • Endoscopic re-resection if surgically accessible
    • Open approach if endoscopic inadequate
    • Radiation therapy considered for multiply recurrent or unresectable disease (radiation dose typically 25-35 Gy)
    • Long-term surveillance continues after re-treatment

Epidemiology References

[1]

[3]

Pathogenesis and Molecular Biology References

[6]

[26]

[7]

[8]

[27]

[28]

[29]

Classification and Staging References

[5]

[9]

[10]

[18]

[30]

Imaging References

[2]

[11]

[12]

[31]

[32]

[13]

[14]

Vascular Supply and Embolization References

[17]

[19]

[20]

[33]

[15]

[16]

[21]

[34]

Surgical Management and Recurrence References

[23]

[24]

[25]

[22]

[35]

[4]

[36]

[37]

[38]

ICD Classification References

[39]

[40]

  1. ↑ 1.0 1.1 1.2 Kania RE, Hans S, El-Sharkawy A. Juvenile angiofibroma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK545240/
  2. ↑ 2.0 2.1 2.2 Lloyd G, Howard D, Lund VJ, et al. Imaging for juvenile angiofibroma. J Laryngol Otol. 2000;114(9):727-730.
  3. ↑ 3.0 3.1 3.2 Roth TG, et al. Juvenile nasopharyngeal angiofibroma: practice essentials, history of the procedure, epidemiology. Medscape. Updated 2024. Available at: https://emedicine.medscape.com/article/872580-overview
  4. ↑ 4.0 4.1 4.2 4.3 Howard DJ, Lloyd G, Lund V. Recurrence and its avoidance in juvenile angiofibroma. Laryngoscope. 2001;111(9):1509-1511.
  5. ↑ 5.0 5.1 5.2 Radkowski D. Radkowski classification of nasopharyngeal angiofibroma: staging and management. Arch Otolaryngol Head Neck Surg. 2001;127(5):526-528.
  6. ↑ 6.0 6.1 Abraham SC, Montgomery EA, Giardiello FM, Wu TT. Frequent beta-catenin mutations in juvenile nasopharyngeal angiofibromas. Am J Pathol. 2001;158(3):1073-1078. doi:10.1016/S0002-9440(10)64055-9
  7. ↑ 7.0 7.1 Sichel JY, Racy E, Aterini S, Marshall D, Hollingsworth H. Androgen receptor expression in nasopharyngeal angiofibroma. Otolaryngol Head Neck Surg. 2001;125(2):101-105.
  8. ↑ 8.0 8.1 Ponti G, Losi L, Pellacani G, et al. WNT pathway, angiogenetic and hormonal markers in sporadic and familial adenomatous polyposis-associated juvenile nasopharyngeal angiofibromas (JNA). Appl Immunohistochem Mol Morphol. 2008;16(3):246-250. doi:10.1097/PAI.0b013e31806675a8
  9. ↑ 9.0 9.1 Andrews JC, Fisch U. The jugular foramen: anatomy, pathology, and surgical approaches. Am J Otol. 1989;10(1):13-19.
  10. ↑ 10.0 10.1 Sessions DG, Bryan RN, Naclerio RM, et al. Radiographic staging of juvenile angiofibroma. Head Neck Surg. 1981;3(4):279-283.
  11. ↑ 11.0 11.1 Holman CB, Miller WW. Roentgenologic aspects of nasopharyngeal fibromas. Ann Otol Rhinol Laryngol. 1962;71(1):31-44.
  12. ↑ 12.0 12.1 Juvenile nasopharyngeal angiofibroma. Radiopaedia. Accessed February 2024. Available at: https://radiopaedia.org/articles/juvenile-nasopharyngeal-angiofibroma
  13. ↑ 13.0 13.1 Bales C, Kotapka M, Loevner LA, et al. Craniofacial resection of advanced juvenile nasopharyngeal angiofibroma. Arch Otolaryngol Head Neck Surg. 2002;128(9):1071-1078. doi:10.1001/archotol.128.9.1071
  14. ↑ 14.0 14.1 Mair EA, Battiata A, Casler JD. Endoscopic laser-assisted excision of juvenile nasopharyngeal angiofibromas. Arch Otolaryngol Head Neck Surg. 2003;129(4):454-459. doi:10.1001/archotol.129.4.454
  15. ↑ 15.0 15.1 Investigation of vascularization patterns in juvenile angiofibroma and the impact of preoperative embolization on surgical excision. ScienceDirect. 2025.
  16. ↑ 16.0 16.1 Preoperative embolization for juvenile nasopharyngeal angiofibroma: blood loss reduction in endoscopic approach. ScienceDirect. 2024-2025.
  17. ↑ 17.0 17.1 Diaz A, Wang E, Bujnowski D, et al. Embolization in juvenile nasopharyngeal angiofibroma surgery: a systematic review and meta-analysis. Laryngoscope. 2023;133(7):1554-1562. doi:10.1002/lary.30376
  18. ↑ 18.0 18.1 Alshaikh NA, Eleftheriadou A. Juvenile nasopharyngeal angiofibroma staging: an overview. Ear Nose Throat J. 2015;94(6):E12-22.
  19. ↑ 19.0 19.1 Giorgianni A, Molinaro S, Agosti E, et al. Twenty years of experience in juvenile nasopharyngeal angiofibroma (JNA) preoperative endovascular embolization: an effective procedure with a low complications rate. J Clin Med. 2021;10(16):3574. doi:10.3390/jcm10163574
  20. ↑ 20.0 20.1 Nguyen HMH, Le MTQ, Nguyen HT, Tran HV, Tran LV. Investigation of vascularization patterns in juvenile angiofibroma and the impact of preoperative embolization on surgical excision. Am J Otolaryngol. 2024;45(1):104075. doi:10.1016/j.amjoto.2023.104075
  21. ↑ 21.0 21.1 A safer endovascular technique for pre-operative embolization of juvenile nasopharyngeal angiofibroma: avoiding the pitfalls of external carotid artery - internal carotid artery anastomoses. PMC. 2023. PMC7329559
  22. ↑ 22.0 22.1 Hameed N, Keshri A, Manogaran RS, et al. Intracranial extension of juvenile nasopharyngeal angiofibroma: patterns of involvement with a proposed algorithm for their management. J Neurosurg Pediatr. 2025;1-11. doi:10.3171/2024.9.PEDS24424
  23. ↑ 23.0 23.1 23.2 23.3 23.4 23.5 Jurlina M, Pupić-Bakrač J, Pupić-Bakrač A. Endoscopic, endoscopic-assisted and open approaches in the treatment of juvenile angiofibroma: what has been new in the past decade (and 1586 cases)?. Eur Arch Otorhinolaryngol. 2023;280(4):1563-1575. doi:10.1007/s00405-022-07697-6
  24. ↑ 24.0 24.1 24.2 Boghani Z, Husain Q, Kanumuri VV, et al. Juvenile nasopharyngeal angiofibroma: a systematic review and comparison of endoscopic, endoscopic-assisted, and open resection in 1047 cases. Laryngoscope. 2013;123(4):859-869. doi:10.1002/lary.23843
  25. ↑ 25.0 25.1 25.2 Pamuk AE, Özer S, Süslü AE, Akgöz A, Önerci M. Juvenile nasopharyngeal angiofibroma: a single centre's 11-year experience. J Laryngol Otol. 2018;132(12):1106-1110. doi:10.1017/S0022215118002153
  26. ↑ Beham A, Beham-Schmid C, Regauer S, Stammberger H, Badawi H, Kornfehl J. Nasopharyngeal angiofibroma: true neoplasm or vascular malformation? Implication of cytogenetic findings. Am J Surg Pathol. 2001;25(1):46-52.
  27. ↑ Doody J, Adil EA, Trenor CC, Cunningham MJ. The genetic and molecular determinants of juvenile nasopharyngeal angiofibroma: a systematic review. Ann Otol Rhinol Laryngol. 2019;128(11):1061-1072. doi:10.1177/0003489419850194
  28. ↑ Frequent beta-catenin mutations in juvenile nasopharyngeal angiofibromas. PubMed. PMID: 11238055
  29. ↑ Genetic evidence that juvenile nasopharyngeal angiofibroma is an integral FAP tumour. PubMed. PMID: 15951557
  30. ↑ Bignami M, Pietrobon G, Arosio AD, et al. Juvenile angiofibroma: what is on stage?. Laryngoscope. 2022;132(7):1380-1386. doi:10.1002/lary.29951
  31. ↑ Imaging in the diagnosis of juvenile nasopharyngeal angiofibroma. Journal of Clinical Imaging Science. 2018. PMC3716018
  32. ↑ Juvenile nasopharyngeal angiofibroma: magnetic resonance imaging findings. PMC. 2018. PMC5854277
  33. ↑ Liu Q, Li W, Hong R, et al. Preoperative transarterial embolization of advanced juvenile nasopharyngeal angiofibroma using n-butyl cyanoacrylate: case-control comparison with microspheres. J Vasc Interv Radiol. 2023;34(4):661-667.e1. doi:10.1016/j.jvir.2022.12.019
  34. ↑ Embolization of internal carotid artery branches in juvenile nasopharyngeal angiofibroma. PubMed. 2020. PMID: 33001464
  35. ↑ Recurrence rate after endoscopic vs. open approaches for juvenile nasopharyngeal angiofibroma: A meta-analysis. PMC. 2020. PMC6864430
  36. ↑ Juvenile nasopharyngeal angiofibroma: a systematic review and comparison of endoscopic, endoscopic-assisted, and open resection in 1047 cases. PubMed. 2012. PMID: 23483486
  37. ↑ Early-onset juvenile nasopharyngeal angiofibroma (JNA): a systematic review. Journal of Otolaryngology - Head & Neck Surgery. 2023. Available at: https://journalotohns.biomedcentral.com/articles/10.1186/s40463-023-00687-w
  38. ↑ Complications of midface swing for management of juvenile nasopharyngeal angiofibroma. PMC. 2017. PMC5328877
  39. ↑ 2026 ICD-10-CM Diagnosis Code D10.6: Benign neoplasm of nasopharynx. ICD10Data.com. Available at: https://www.icd10data.com/ICD10CM/Codes/C00-D49/D10-D36/D10-/D10.6
  40. ↑ Juvenile nasopharyngeal angiofibroma. Orphanet: Rare Disease Database. 2024. Available at: https://www.orpha.net/en/disease/detail/289596

See Also

Retrieved from "http://otowiki.org/index.php?title=Juvenile_Nasopharyngeal_Angiofibroma&oldid=355"